Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 17, 2018. The document serves as a transaction notification under the Securities Exchange Act of 1934, detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions executed on October 12, 2018.
| Instrument | Transaction Price | Exchange | Total Volume (Shares/ADSs) |
|---|---|---|---|
| Ordinary Shares (GBP) | £14.516 | London Stock Exchange (XLON) | 6,063 |
| American Depositary Shares (USD) | $38.47 | New York Stock Exchange (XNYS) | 194 |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It documents routine share acquisitions resulting from the re-investment of dividends paid on October 11, 2018, under the Company's Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed automatically via dividend re-investment plans and do not represent discretionary trading or unusual items.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs to ensure compliance with insider trading policies.
- Confirm the transaction date (October 12, 2018) aligns with the dividend payment date (October 11, 2018).
- Check the aggregate volume of Ordinary Shares (6,063) and ADSs (194) against the company's total outstanding share count to assess dilution impact (negligible).
- Review the specific roles of the individuals involved (e.g., CEO, CFO, Presidents) to confirm their status as PDMRs.